Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stergios A Polyzos

Showing results (221-230 of 431) with videos related to

Pageof 44
Sort By:
Endocrine|January 4, 2026
Correction to: Repurposing Levothyroxine for managing metabolic dysfunction-associated steatotic liver diseaseLeonidas H Duntas, Stergios A Polyzos, Ulrike Gottwald-Hostalek, et al.
Metabolism: Clinical and Experimental|September 14, 2016
Activin A and follistatin in patients with nonalcoholic fatty liver diseaseStergios A Polyzos, Jannis Kountouras, Athanasios D Anastasilakis, et al.
Medical Hypotheses|April 13, 2011
Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesisAthanasios D Anastasilakis, Stergios A Polyzos, Chrysostomos D Anastasilakis, et al.
Diabetes, Obesity & Metabolism|May 19, 2022
Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implicationsIlias D Vachliotis, Athanasios D Anastasilakis, Antonis Goulas, et al.
Bone Reports|February 20, 2026
Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosisAthanasios D Anastasilakis, Polyzois Makras, Stergios A Polyzos, et al.
Annals of Gastroenterology|March 23, 2026
Impact of <i>Helicobacter pylori</i> eradication on the progression of Correa's cascadeJannis Kountouras, Stergios A Polyzos, Ioannis S Papanikolaou, et al.
Bone|June 14, 2020
The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosisPolyzois Makras, Socrates E Papapoulos, Stergios A Polyzos, et al.
American Journal of Ophthalmology|November 24, 2011
Helicobacter pylori infection as a risk factor for both primary open-angle glaucoma and pseudoexfoliative glaucoma in Thessaloniki Eye StudyJannis Kountouras, Christos Zavos, Georgios Sakkias, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|February 5, 2021
Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab DiscontinuationAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Gastroenterology and Hepatology|March 10, 2026
A Potential Impact of Helicobacter pylori Infection on Gastroesophageal Reflux DiseaseJannis Kountouras, Stergios A Polyzos, Evangelos Kazakos, et al.
Pageof 44

Showing results (221-230 of 431) with videos related to

Sort By:
Pageof 44
Endocrine|January 4, 2026
Correction to: Repurposing Levothyroxine for managing metabolic dysfunction-associated steatotic liver diseaseLeonidas H Duntas, Stergios A Polyzos, Ulrike Gottwald-Hostalek, et al.
Metabolism: Clinical and Experimental|September 14, 2016
Activin A and follistatin in patients with nonalcoholic fatty liver diseaseStergios A Polyzos, Jannis Kountouras, Athanasios D Anastasilakis, et al.
Medical Hypotheses|April 13, 2011
Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesisAthanasios D Anastasilakis, Stergios A Polyzos, Chrysostomos D Anastasilakis, et al.
Diabetes, Obesity & Metabolism|May 19, 2022
Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implicationsIlias D Vachliotis, Athanasios D Anastasilakis, Antonis Goulas, et al.
Bone Reports|February 20, 2026
Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosisAthanasios D Anastasilakis, Polyzois Makras, Stergios A Polyzos, et al.
Annals of Gastroenterology|March 23, 2026
Impact of <i>Helicobacter pylori</i> eradication on the progression of Correa's cascadeJannis Kountouras, Stergios A Polyzos, Ioannis S Papanikolaou, et al.
Bone|June 14, 2020
The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosisPolyzois Makras, Socrates E Papapoulos, Stergios A Polyzos, et al.
American Journal of Ophthalmology|November 24, 2011
Helicobacter pylori infection as a risk factor for both primary open-angle glaucoma and pseudoexfoliative glaucoma in Thessaloniki Eye StudyJannis Kountouras, Christos Zavos, Georgios Sakkias, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|February 5, 2021
Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab DiscontinuationAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Gastroenterology and Hepatology|March 10, 2026
A Potential Impact of Helicobacter pylori Infection on Gastroesophageal Reflux DiseaseJannis Kountouras, Stergios A Polyzos, Evangelos Kazakos, et al.
Pageof 44